Galectin Therapeutics
GALT
61 hedge funds and large institutions have $20M invested in Galectin Therapeutics in 2018 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 12 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
2% more funds holding
Funds holding: 60 → 61 (+1)
1.51% more ownership
Funds ownership: 12.56% → 14.08% (+1.5%)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
38% less call options, than puts
Call options by funds: $1.3M | Put options by funds: $2.12M
45% less capital invested
Capital invested by funds: $36.3M → $20M (-$16.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$804K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$693K |
| 3 |
LCM
Laurion Capital Management
New York
|
+$451K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
+$365K |
| 5 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$311K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$1.56M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.38M |
| 3 |
FFA
First Foundation Advisors
Irvine,
California
|
-$1.09M |
| 4 |
Millennium Management
New York
|
-$676K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$238K |
GALT Hedge Fund Activity: Q4 2018 in Review
61 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q4 2018, worth a combined $20M — down 45% from $36.3M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new GALT positions and 12 closed out — a net gain of 1 holder — while 15 added to existing stakes and 11 trimmed.
The largest buyer was Barclays, adding an estimated $804K. The largest seller was Invesco, exiting entirely with an estimated $1.56M sold.
- 61 institutional investors held Galectin Therapeutics (GALT) as of Q4 2018, up from 60 in Q3 2018.
- Funds reported $20M of Galectin Therapeutics stock for Q4 2018, down 45% quarter-over-quarter.
- 13 funds opened new Galectin Therapeutics positions in Q4 2018 and 12 closed out, a net change of +1 holder.
- The largest Galectin Therapeutics buyer in Q4 2018 was Barclays, an estimated $804K added.
- The largest Galectin Therapeutics seller in Q4 2018 was Invesco, an estimated $1.56M sold.
Based on aggregated 13F filings for Q4 2018.